Funding for this research was provided by:
Pontificia Universidade Católica do Paraná (NA)
Fresenius Medical Care North America (NA)
Received: 1 October 2019
Accepted: 12 May 2020
First Online: 25 May 2020
Ethics approval and consent to participate
: The HDFIT trial is was performed under a protocol approved by Pontifícia Universidade Católica do Paraná Ethics Review Board (Central tracking #: 54926916.7.1001.0020; Approval #: 1.538.784). All participants had provided written informed consent prior to participation in any study activities.
: Not applicable.
: JWL, MH, MG are students at Pontifícia Universidade Católica do Paraná. JWL, HH, LAU, are employees of Fresenius Medical Care. MH, PK, JGR are employees of Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care North America. PBG receives travel support from Fresenius Medical Care. CEPF, ALCN receive consulting fees and speaker honorarium from Fresenius Medical Care. CEPF receives lecture fees and travel support from Fresenius Medical Care, Alexion, Baxter, and Astra Zeneca, and is employed by Pontifícia Universidade Católica do Rio Grande do Sul. ABLB is an employee of Fresenius Medical Care Brazil. LAU, PK have share options/ownership in Fresenius Medical Care. PK receives author honorarium from Up-To-Date and is on the Editorial Board of Blood Purification and Kidney and Blood Pressure Research. RPF, TPM are employed by Pontifícia Universidade Católica do Paraná. RPF, CEPF, TPM, MEFC are recipients of scholarships from the Brazilian Council for Research (CNPq). MEFC is employee by Federal University of São Paulo, and receives research grants, consulting fees, and honoraria from Baxter Healthcare and Fresenius Medical Care. RPF is employed by Arbor Research Collaborative for Health, and receives research grants, consulting fees, and honoraria from Astra Zeneca, Novo Nordisc, Akebia, and Fresenius Medical Care. All other authors declare no relevant conflicts of interest.